Recent advances in pharmacological treatment of heart failure

Link to article at PubMed

Eur J Clin Invest. 2021 May 27:e13624. doi: 10.1111/eci.13624. Online ahead of print.


Over the last years, several trials offered new evidence on heart failure (HF) treatment. For HF with reduced left ventricular ejection fraction, type 2 sodium-glucose cotransporter inhibitors, aside from sacubitril-valsartan, demonstrated extraordinary efficacy in ameliorating patients' prognosis. Some new molecules (e.g. vericiguat, omecamtiv mecarbil and ferric carboxymaltose) correct iron deficiency and have shown to be capable of furthering reducing the burden of HF hospitalisation.

PMID:34043809 | DOI:10.1111/eci.13624

Leave a Reply

Your email address will not be published.